For the quarter ending 2025-09-30, NGNE had $12,192K increase in cash & cash equivalents over the period. -$19,635K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total research and development expenses | 54,372 | - |
| Total general and administrative expenses | 21,427 | - |
| Other income | 10,183 | - |
| Net loss | -65,616 | - |
| Stock-based compensation expense | 3,365 | 7,456 |
| Depreciation and amortization of property and equipment | 764 | 1,503 |
| Asset impairment | 0 | 0 |
| Non-cash operating lease expense | 207 | 399 |
| Amortization of finance lease right-of-use assets | 12 | 26 |
| Amortization and accretion of premiums/discounts on held-to-maturity investments | 816 | 3,220 |
| Change in contingent value rights liability | -822 | 78 |
| Prepaid expenses and other current assets | 417 | 949 |
| Other assets | -33 | 121 |
| Accounts payable | -501 | 719 |
| Accrued expenses and other liabilities | 365 | -31 |
| Operating lease liabilities | -745 | -1,433 |
| Net cash used in operating activities | -19,508 | -40,236 |
| Purchases of property and equipment | 127 | 928 |
| Purchases of held-to-maturity investments | 77,383 | 149,367 |
| Proceeds from maturities of held-to-maturity investments | 99,500 | 112,700 |
| Net cash used in investing activities | 21,990 | -37,595 |
| Proceeds from sale of common stock in at-the-market sales agreement, net of offering costs | 9,800 | - |
| Payment of deferred offering costs related to at-the-market sales agreement | 166 | - |
| Offering costs in connection with pre-closing financing | 0 | 0 |
| Transaction costs related to reverse merger | 0 | 0 |
| Proceeds from the issuance of common stock upon exercise of options | 89 | 87 |
| Principal payments on finance leases | 13 | 29 |
| Net cash provided by (used in) financing activities | 9,710 | 58 |
| Net decrease in cash, cash equivalents and restricted cash | 12,192 | -77,773 |
| Cash and cash equivalents at beginning of period | 136,925 | - |
| Cash and cash equivalents at end of period | 71,344 | - |
Neurogene Inc. (NGNE)
Neurogene Inc. (NGNE)